<DOC>
	<DOCNO>NCT00219739</DOCNO>
	<brief_summary>To test whether increase dose imatinib combine IFNalpha ara-C increase rate molecular response ( measured decrease BCR-ABL transcripts 12 month treatment ) patient previously untreated CML chronic phase . To compare overall survival select arm accord molecular response 1 year randomization reference arm .</brief_summary>
	<brief_title>STI571 ProspectIve RandomIzed Trial : SPIRIT</brief_title>
	<detailed_description>Imatinib 400 mg daily emerge preferred therapy newly diagnose CML patient undergo allogeneic stem cell transplant . A phase III randomize study , compare imatinib 400 mg per day interferon plus cytarabine newly diagnose chronic phase CML patient enrol 1106 patient June 2000 January 2001 . 553 patient randomized treatment . For comparative purpose , 6 month , 75 % patient randomize imatinib obtain major cytogenetic response 51 % complete response . Despite impressive result , minority patient treat imatinib study achieve molecular remission . When analyzed log reduction Bcr-Abl transcript level use quantitative RT-PCR , 39 % patient achieve 3-log reduction Bcr-Abl level , 13 % 3 % achieve 4- 5-log reduction , respectively.2 To improve upon result , various group try high dos imatinib , combination imatinib interferon alpha cytarabine . Each study use cytogenetic response major endpoint . Each therapy increase toxicity compare 400 mg imatinib alone rate molecular remission report . Thus purpose study first determine whether high dos imatinib combine Imatinib interferon Ara-C would result high rate molecular response , good survival .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Patients 18 year age Patients BcrAbl positive CML chronic phase . Patients within 14 week diagnosis previously untreated CML except hydroxyurea and/or anagrelide . No evidence extramedullary leukemic involvement , exception hepatosplenomegaly ECOG performance score 02 acceptable hepatic , renal , cardiac function Informed consent sign Depressive syndrome control Uncontrolled medical illness . Women childbearing potential male patient unwilling unable use adequate method avoid pregancy entire period study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>CML</keyword>
	<keyword>Imatinib</keyword>
	<keyword>Interferon</keyword>
	<keyword>Cytarabine</keyword>
</DOC>